Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Small adult patients with end-stage liver disease waitlisted for liver transplantation may face a shortage of size-matched liver grafts. This may result in longer waiting times, increased waitlist removal, and waitlist mortality. This study aims to assess access to transplantation in transplant candidates with below-average bodyweight throughout the Eurotransplant region.

Methods: Patients above 16 y of age listed for liver transplantation between 2010 and 2015 within the Eurotransplant region were eligible for inclusion. The effect of bodyweight on chances of receiving a liver graft was studied in a Cox model corrected for lab-Model for End-stage Liver Disease (MELD) score updates fitted as time-dependent variable, blood type, listing for malignant disease, and age. A natural spline with 3 degrees of freedom was used for bodyweight and lab-MELD score to correct for nonlinear effects.

Results: At the end of follow-up, the percentage of transplanted, delisted, and deceased waitlisted patients was 49.1%, 17.9%, and 24.3% for patients with a bodyweight <60 kg (n = 1267) versus 60.1%, 15.1%, and 18.6% for patients with a bodyweight ≥60 kg (n = 10 520). To reach comparable chances for transplantation, 60-kg and 50-kg transplant candidates are estimated to need, respectively, up to 2.8 and 4.0 more lab-MELD points than 80-kg transplant candidates.

Conclusions: Decreasing bodyweight was significantly associated with decreased chances to receive a liver graft. This resulted in substantially longer waiting times, higher delisting rates, and higher waitlist mortality for patients with a bodyweight <60 kg.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11042512PMC
http://dx.doi.org/10.1097/TP.0000000000004804DOI Listing

Publication Analysis

Top Keywords

liver transplantation
12
eurotransplant region
8
end-stage liver
8
liver disease
8
liver
7
quantifying disadvantage
4
disadvantage small
4
small recipient
4
recipient size
4
size liver
4

Similar Publications

Post-recurrence Survival After Liver Transplantation for Hepatocellular Carcinoma.

Transplantation

September 2025

General Surgery and Liver Transplantation Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.

Background: Mortality after liver transplantation (LT) for hepatocellular carcinoma (HCC) is mainly driven by HCC recurrence. We sought to determine whether post-recurrence survival (PRS) has improved during the last 2 decades.

Methods: Using the Scientific Registry of Transplant Recipients, we included all patients who underwent LT for HCC between 2003 and 2020 and experienced HCC recurrence.

View Article and Find Full Text PDF

Fever, cytopenia, and splenomegaly in a liver transplant patient.

Am J Transplant

September 2025

Section of Abdominal Transplantation, Department of Surgery, Washington University in St. Louis, St. Louis, Missouri, USA. Electronic address:

View Article and Find Full Text PDF

Empagliflozin alleviates hepatic ischemia-reperfusion injury by inhibiting c-Myc through the JAK1-STAT3 signaling pathway.

Int Immunopharmacol

September 2025

Department of Hepatobiliary and Hydatid Disease, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China; State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Urumqi, China. Electronic address:

Hepatic ischemia-reperfusion injury (HIRI) is a critical factor affecting the outcomes of liver surgeries, with inflammation and apoptosis playing pivotal roles in its pathogenesis. Empagliflozin, an anti-diabetic drug, has demonstrated hepatoprotective effects in various liver diseases, but its role in HIRI remains unclear. This study aimed to explore the protective mechanisms of empagliflozin against HIRI.

View Article and Find Full Text PDF

Heart transplant candidates that are highly sensitized against human leukocyte antigens (HLA) face ongoing challenge in finding immunologically compatible donors. Desensitization strategies aimed at reducing HLA antibody titers have variable success rates. Imlifidase, a novel immunoglobulin G-degrading enzyme derived from Streptococcus pyogenes has been successfully used to eliminate pre-formed antibodies in sensitized kidney transplant recipients.

View Article and Find Full Text PDF